ClinicalTrials.gg
CompletedNCT02253173REJOICEUpdated May 25, 2017Results posted

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

A Phase 3 interventional study of Estradiol and Placebo in Vulvovaginal Atrophy, Menopause and Dyspareunia, sponsored by TherapeuticsMD. Completed at 105 sites in 2 countries. Open to female participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-25.

Sponsored by TherapeuticsMD · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
764
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.

Enrollment
3rd of 53
764 · median 60
Started
2014
with 3 others
Phase 3
13 of 56
none open now
Registered
17th of 56
by date
Lead sponsor
2 of 56
TherapeuticsMD

Among the 56 studies in Dyspareunia with a site in United States, this one is the 3rd largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2014, is one of 13 in phase 3, and was the 17th registered.

Dyspareunia

159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.

Browse Dyspareunia studies →

Open to participants now

8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 40 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Dyspareunia with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.

03

Conditions studied

  • Vulvovaginal Atrophy
  • Menopause
  • Dyspareunia
  • Painful Intercourse

Browse trials for

Keywords

  • VVA
  • Painful Sex
  • Postmenopausal
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. female subjects between the ages of 40 and 75 years (at the time of randomization) with at least:

    • 12 months of spontaneous amenorrhea (women \<55 years of age with a history of hysterectomy without bilateral oophorectomy prior to natural menopause must have follicle stimulating hormone (FSH) levels > 40 mIU/mL), OR
    • 6 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) levels > 40mlU/mL OR
    • At least 6 weeks postsurgical bilateral oophorectomy.
  2. ≤5% superficial cells on vaginal cytological smear
  3. Vaginal pH > 5.0
  4. Moderate to severe symptom of vaginal pain associated with sexual activity considered the most bothersome vaginal symptom by the subject at screening visit 1A.
  5. Moderate to severe symptom of vaginal pain associated with sexual activity at screening visit 1B.
  6. Onset of moderate to severe dyspareunia in the postmenopausal years.
  7. Subjects should be sexually active (i.e. have sexual activity with vaginal penetration within approximately 1 month of screening visit 1A).
  8. Subjects should anticipate having sexual activity (with vaginal penetration) during the conduct of the trial.
  9. For subjects with an intact uterus: Subjects must have an acceptable result from an evaluable screening endometrial .
  10. Subjects who have a (BMI) less than or equal to 38 kg/m2. BMI values should be rounded to the nearest integer (ex. 32.4 rounds down to 32, while 26.5 rounds up to 27).
  11. In the opinion of the investigator, the subject will comply with the protocol and has a high probability of completing the study.

Exclusion criteria

Exclusion Criteria:

  1. Use of the following:

    1. Oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening visit 1A (can enter washout);
    2. Use of transdermal hormone products within 4 weeks before screening visit 1A (can enter washout);
    3. Use of vaginal hormone products (rings, creams, gels) within 4 weeks before screening visit1A (can enter washout);
    4. Use of intrauterine progestins within 8 weeks before screening visit 1A (can enter washout);
    5. Use of progestin implants/injectables or estrogen pellets/injectables within 6 months before screening visit 1A (cannot enter washout);
    6. Use of vaginal lubricants or moisturizers within 7 days before the screening visit 1B vaginal pH assessment.
  2. A history or active presence of medical disease that might confound the study or be detrimental to the subject, examples include:

    1. to estrogens;
    2. Endometrial hyperplasia;
    3. Undiagnosed vaginal bleeding;
    4. Have a history of a chronic liver or kidney dysfunction/disorder (e.g., or chronic renal failure);
    5. Thrombophlebitis, thrombosis or thromboembolic disorders;
    6. Cerebrovascular accident, stroke, or ;
    7. Myocardial infarction or ischemic heart disease;
    8. or treatment for malignancy, within the previous 5 years, with the exception of basal cell carcinoma of the skin or squamous cell carcinoma of the skin. A history of estrogen dependent neoplasia, breast cancer, melanoma or any gynecologic cancer, at any time, excludes the subject;
    9. Endocrine disease (except for controlled hypothyroidism or controlled non-insulin dependent diabetes mellitus).
  3. Recent history of known alcohol or drug abuse.
  4. History of sexual abuse or spousal abuse that, in the opinion of the PI, may interfere with the subject's assessment of vaginal pain with sexual activity.
  5. Current history of Heavy smoking (more than 15 cigarettes per day) or use of e-cigarettes.
  6. Use of an intrauterine device within 12 weeks before screening visit 1A.
  7. Use of an drug within 60 days before screening visit 1A.
  8. Any clinically important abnormalities on screening physical exam, assessments, , or laboratory tests, such as:

    1. Unresolved cervical cytologic smear report of atypical glandular cells of undetermined significance (AGUS) or atypical squamous cells of undetermined significance (ASCUS).

      Cervical cytologic smear report of low-grade squamous intraepithelial lesion (SIL) or greater, CIN1 or greater, or any reported dysplasia; Subjects with ASCUS are eligible only if high risk human papilloma virus (HPV) result is negative.

    2. Unresolved findings suspicious for malignancy on the breast exam; incomplete mammogram result (BI-RADS 0) or unresolved findings suggestive of malignant changes or findings requiring short interval follow-up on the prestudy mammogram (subjects must have mammography result of BI-RADS 1 or 2 to enroll.) Mammogram may be performed within 9 months prior to Visit 2 (randomization) with documentation available. (The site must obtain a copy of the official report for the subject's study file, and it must be verified that the mammogram itself is available if needed for additional assessment);
    3. In subjects with intact uterus: have a screening endometrial sample that is found by both primary pathologists to have endometrial tissue insufficient for diagnosis, no endometrium identified, or no tissue identified. (With the approval of the Medical Monitor, the screening endometrial biopsy may be repeated once);
    4. In subjects with intact uterus: an endometrial biopsy report by one central pathologist at screening with one of the following:

      • Endometrial hyperplasia endometrial cancer, proliferative endometrium, weakly proliferative endometrium, disordered proliferative pattern; OR
      • Endometrial polyps with hyperplasia, glandular atypia of any degree (e.g., atypical nuclei) or cancer;
    5. Vulvar or vaginal inflammatory condition such as a contact or allergic dermatitis, lichen sclerosis or other pathological findings;
    6. Presence of suspicious vulvar or vaginal lesions for dysplasia, malignancy or other pathology other than atrophy;
    7. Painful genital warts or localized areas of ulceration;
    8. A history of active, chronic pelvic pain;
    9. Interstitial cystitis;
    10. Serum (ALT) or serum aspartate aminotransferase (AST) greater than 1.5 times the for the laboratory used;
    11. Fasting total cholesterol greater than 300 mg/dL (7.77 mmol/L) or triglycerides greater than 300 mg/dL (3.39 mmol/L);
    12. Fasting blood glucose greater than 125 mg/dL (6.94 mmol/L) with a of greater than or equal to 6.5%;
    13. Uncontrolled hypertension; subjects with elevated sitting blood pressure, greater than 140 mm Hg systolic or greater than 90 mm Hg diastolic and may not be using more than 2 antihypertensive medications for the treatment of hypertension;
    14. Clinically significant abnormal 12-lead ECG (such as myocardial infarction or other findings suggestive of ischemia)
  9. Be known to be pregnant or have a positive urine pregnancy test. (Note: A pregnancy test is not required for subjects who have had bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or are 55 years old or greater and have experienced cessation of menses for at least 1 year.
  10. Current use of marijuana.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
764 participants (actual)

Study arms

  • Experimental
    Estradiol 4mcg Vaginal Softgel Capsule

    Estradiol 4mcg Vaginal Softgel Capsule

    Drug: Estradiol

  • Experimental
    Estradiol 10mcg Vaginal Softgel Capsule

    Estradiol 10mcg Vaginal Softgel Capsule

    Drug: Estradiol

  • Experimental
    Estradiol 25mcg Vaginal Softgel Capsule

    Estradiol 25mcg Vaginal Softgel Capsule

    Drug: Estradiol

  • Placebo comparator
    Placebo Vaginal Softgel Capsule

    Placebo Vaginal Softgel Capsule

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Co-Primary Efficacy Endpoint - Vaginal Superficial Cells

    • Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

    Time frame: Baseline and 12 Weeks

  2. Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells

    • Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

    Time frame: Baseline and 12 Weeks

  3. Co-Primary Efficacy Endpoint - Vaginal pH

    • Change from Baseline to Week 12 in vaginal pH as compared to placebo

    Time frame: Baseline and 12 Weeks

  4. Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia)

    • Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Secondary Efficacy Endpoints - Vaginal Superficial Cells

    • Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

    Time frame: Baseline and Week 2

  2. Secondary Efficacy Endpoints- Vaginal Superficial Cells

    Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

    Time frame: Baseline and Week 6

  3. Secondary Efficacy Endpoints - Vaginal Superficial Cells

    Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

    Time frame: Baseline and Week 8

  4. Secondary Efficacy Endpoints - Vaginal Parabasal Cells

    Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

    Time frame: Baseline and Week 2

  5. Secondary Efficacy Endpoints - Vaginal Parabasal Cells

    Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

    Time frame: Baseline and Week 6

  6. Secondary Efficacy Endpoints - Vaginal Parabasal Cells

    Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

    Time frame: Baseline and Week 8

  7. Secondary Efficacy Endpoints - Vaginal pH

    Change from Baseline to Week 2 in vaginal pH as compared to placebo

    Time frame: Baseline and Week 2

  8. Secondary Efficacy Endpoints - Vaginal pH

    Change from Baseline to Week 6 in vaginal pH as compared to placebo

    Time frame: Baseline and Week 6

  9. Secondary Efficacy Endpoints - Vaginal pH

    Change from Baseline to Week 8 in vaginal pH as compared to placebo

    Time frame: Baseline and Week 8

  10. Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

    Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2

    Time frame: Baseline and Week 2

  11. Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

    Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6

    Time frame: Baseline and Week 6

  12. Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

    Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8

    Time frame: Baseline and Week 8

  13. Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

    Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2

    Time frame: Baseline and Week 2

  14. Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

    Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6

    Time frame: Baseline and Week 6

  15. Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

    Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8

    Time frame: Baseline and Week 8

  16. Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

    Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12

    Time frame: Baseline and Week 12

  17. Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

    Change from Baseline to Week 2 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2

    Time frame: Baseline and Week 2

  18. Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

    Change from Baseline to Week 6 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6

    Time frame: Baseline and Week 6

  19. Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

    Change from Baseline to Week 8 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8

    Time frame: Baseline and Week 8

  20. Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

    Change from Baseline to Week 12 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12

    Time frame: Baseline and Week 12

  21. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

    Change from Baseline to Week 2 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 2

    Time frame: Baseline and Week 2

  22. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

    Change from Baseline to Week 6 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 6

    Time frame: Baseline to Week 6

  23. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

    Change from Baseline to Week 8 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 8

    Time frame: Baseline to Week 8

  24. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

    Change from Baseline to Week 12 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 12

    Time frame: Baseline and Week 12

  25. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

    Change from Baseline to Week 2 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 2

    Time frame: Baseline and Week 2

  26. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

    Change from Baseline to Week 6 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 6

    Time frame: Baseline and Week 6

  27. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

    Change from Baseline to Week 8 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 8

    Time frame: Baseline and Week 8

  28. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

    Change from Baseline to Week 12 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 12

    Time frame: Baseline and Week 12

  29. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

    Change from Baseline to Week 2 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 2

    Time frame: Baseline and Week 2

  30. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

    Change from Baseline to Week 6 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 6

    Time frame: Baseline and Week 6

  31. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

    Change from Baseline to Week 8 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 8

    Time frame: Baseline and Week 8

  32. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

    Change from Baseline to Week 12 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 12

    Time frame: Baseline and Week 12

  33. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

    Change from Baseline to Week 2 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain) = 3 Severity was assessed by the Investigator at Baseline and Week 2

    Time frame: Baseline and Week 2

  34. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

    Change from Baseline to Week 6 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 6

    Time frame: Baseline and Week 6

  35. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

    Change from Baseline to Week 8 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 8

    Time frame: Baseline and Week 8

  36. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

    Change from Baseline to Week 12 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 12

    Time frame: Baseline and Week 12

  37. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score

    Change from Baseline to Week 12 in FSFI Total Score as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

    Time frame: Baseline and Week 12

  38. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal

    Change from Baseline to Week 12 in FSFI Domain Score (Arousal) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

    Time frame: Baseline and Week 12

  39. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire

    Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

    Time frame: Baseline and Week 12

  40. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication

    Change from Baseline to Week 12 in FSFI Domain Score (Lubrication) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

    Time frame: Baseline and Week 12

  41. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm

    Change from Baseline to Week 12 in FSFI Domain Score (Orgasm) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

    Time frame: Baseline and Week 12

  42. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain

    Change from Baseline to Week 12 in FSFI Domain Score (Pain) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

    Time frame: Baseline and Week 12

  43. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction

    Change from Baseline to Week 12 in FSFI Domain Score (Satisfaction) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

    Time frame: Baseline and Week 12

Other outcomes

  1. PK Substudy - Hormone Concentration Assessments (Serum Estradiol, Estrone and Estrone Conjugates; SHBG)

    Blood samples will be obtained from a subset of subjects at pre-selected sites to characterize PK parameters (AUC, tmax, Cmin, Cmax, Cavg) and to measure SHBG

    Time frame: Pre-treatment, Day 2, Weeks 2 and 12

07

Results

Posted May 25, 2017

Participant flow

Participant flow — Overall Study
MilestoneEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Started191191190192
Completed175174177178
Not completed16171314

Outcome measures

PrimaryCo-Primary Efficacy Endpoint - Vaginal Superficial Cells

• Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

Time frame:
Baseline and 12 Weeks
Reported as:
Least squares mean · percentage of vaginal superficial cells
Co-Primary Efficacy Endpoint - Vaginal Superficial Cells
percentage of vaginal superficial cellsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo
Co-Primary Efficacy Endpoint - Vaginal Superficial Cells17.50 ± 1.54216.72 ± 1.54023.20 ± 1.5295.63 ± 1.537
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
PrimaryCo-Primary Efficacy Endpoint - Vaginal Parabasal Cells

• Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

Time frame:
Baseline and 12 Weeks
Reported as:
Least squares mean · percentage of vaginal parabasal cells
Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells
percentage of vaginal parabasal cellsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo
Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells-40.63 ± 1.755-44.07 ± 1.751-45.55 ± 1.745-6.73 ± 1.750
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
PrimaryCo-Primary Efficacy Endpoint - Vaginal pH

• Change from Baseline to Week 12 in vaginal pH as compared to placebo

Time frame:
Baseline and 12 Weeks
Reported as:
Least squares mean · pH units
Co-Primary Efficacy Endpoint - Vaginal pH
pH unitsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo
Co-Primary Efficacy Endpoint - Vaginal pH-1.32 ± 0.066-1.42 ± 0.066-1.34 ± 0.066-0.28 ± 0.066
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
PrimaryCo-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia)

• Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo
Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia)-1.52 ± 0.071-1.69 ± 0.071-1.69 ± 0.071-1.28 ± 0.070
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = 0.0149
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Superficial Cells

• Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · percentage of vaginal superficial cells
Secondary Efficacy Endpoints - Vaginal Superficial Cells
percentage of vaginal superficial cellsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Superficial Cells31.35 ± 1.49631.93 ± 1.48838.85 ± 1.5006.05 ± 1.498
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints- Vaginal Superficial Cells

Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · percentage of vaginal superficial cells
Secondary Efficacy Endpoints- Vaginal Superficial Cells
percentage of vaginal superficial cellsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints- Vaginal Superficial Cells18.41 ± 1.53616.88 ± 1.54322.65 ± 1.5325.43 ± 1.525
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Superficial Cells

Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · percentage of vaginal superficial cells
Secondary Efficacy Endpoints - Vaginal Superficial Cells
percentage of vaginal superficial cellsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Superficial Cells19.04 ± 1.56117.41 ± 1.55823.88 ± 1.5545.98 ± 1.551
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Parabasal Cells

Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · percentage of vaginal parabasal cells
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
percentage of vaginal parabasal cellsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Parabasal Cells-40.23 ± 1.720-44.42 ± 1.710-45.60 ± 1.723-7.00 ± 1.720
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Parabasal Cells

Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · percentage of vaginal parabasal cells
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
percentage of vaginal parabasal cellsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Parabasal Cells-39.36 ± 1.750-43.55 ± 1.752-45.61 ± 1.746-9.23 ± 1.741
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Parabasal Cells

Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · percentage of vaginal parabasal cells
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
percentage of vaginal parabasal cellsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Parabasal Cells-41.87 ± 1.768-43.78 ± 1.764-45.08 ± 1.762-7.86 ± 1.760
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal pH

Change from Baseline to Week 2 in vaginal pH as compared to placebo

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · pH units
Secondary Efficacy Endpoints - Vaginal pH
pH unitsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal pH-1.23 ± 0.064-1.37 ± 0.064-1.30 ± 0.065-0.28 ± 0.064
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal pH

Change from Baseline to Week 6 in vaginal pH as compared to placebo

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · pH units
Secondary Efficacy Endpoints - Vaginal pH
pH unitsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal pH-1.32 ± 0.066-1.40 ± 0.066-1.48 ± 0.066-0.30 ± 0.065
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal pH

Change from Baseline to Week 8 in vaginal pH as compared to placebo

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · pH units
Secondary Efficacy Endpoints - Vaginal pH
pH unitsEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal pH-1.35 ± 0.067-1.46 ± 0.067-1.45 ± 0.066-0.38 ± 0.066
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)-0.99 ± 0.072-1.08 ± 0.072-1.02 ± 0.073-0.76 ± 0.072
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0260
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0019
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0105
SecondarySecondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)-1.30 ± 0.072-1.37 ± 0.072-1.48 ± 0.072-1.03 ± 0.070
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0069
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0009
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)-1.52 ± 0.073-1.64 ± 0.074-1.62 ± 0.075-1.15 ± 0.072
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0003
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)-0.86 ± 0.066-1.01 ± 0.065-0.96 ± 0.066-0.72 ± 0.066
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.1269
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0019
  • Estradiol 25mcg Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0082
SecondarySecondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)-1.14 ± 0.067-1.27 ± 0.068-1.23 ± 0.067-0.90 ± 0.067
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0094
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0005
SecondarySecondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)-1.25 ± 0.069-1.44 ± 0.068-1.34 ± 0.068-1.01 ± 0.068
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0128
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0008
SecondarySecondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)-1.27 ± 0.068-1.47 ± 0.067-1.47 ± 0.067-0.97 ± 0.067
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0014
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

Change from Baseline to Week 2 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)-0.47 ± 0.054-0.56 ± 0.053-0.51 ± 0.054-0.47 ± 0.054
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.9616
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.2439
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.6518
SecondarySecondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

Change from Baseline to Week 6 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)-0.57 ± 0.055-0.64 ± 0.055-0.61 ± 0.055-0.55 ± 0.055
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.7829
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.2328
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.4118
SecondarySecondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

Change from Baseline to Week 8 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)-0.74 ± 0.056-0.76 ± 0.056-0.73 ± 0.056-0.59 ± 0.056
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0639
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0356
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0914
SecondarySecondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

Change from Baseline to Week 12 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)-0.75 ± 0.055-0.81 ± 0.055-0.77 ± 0.055-0.60 ± 0.055
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0503
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0055
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0263
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

Change from Baseline to Week 2 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 2

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)-0.69 ± 0.048-0.77 ± 0.047-0.78 ± 0.048-0.40 ± 0.047
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

Change from Baseline to Week 6 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 6

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)-0.82 ± 0.049-0.93 ± 0.049-0.89 ± 0.049-0.50 ± 0.048
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

Change from Baseline to Week 8 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 8

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)-0.98 ± 0.050-1.04 ± 0.050-0.99 ± 0.049-0.50 ± 0.049
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

Change from Baseline to Week 12 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 12

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)-0.97 ± 0.049-1.06 ± 0.049-0.96 ± 0.049-0.60 ± 0.049
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

Change from Baseline to Week 2 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 2

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)-0.85 ± 0.049-0.87 ± 0.049-0.93 ± 0.049-0.53 ± 0.049
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

Change from Baseline to Week 6 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 6

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)-0.97 ± 0.051-1.02 ± 0.051-1.01 ± 0.051-0.61 ± 0.050
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

Change from Baseline to Week 8 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 8

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)-1.03 ± 0.052-1.08 ± 0.051-1.08 ± 0.051-0.66 ± 0.051
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

Change from Baseline to Week 12 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 12

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)-0.97 ± 0.051-1.07 ± 0.051-1.01 ± 0.050-0.60 ± 0.050
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

Change from Baseline to Week 2 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 2

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)-0.76 ± 0.049-0.76 ± 0.049-0.76 ± 0.049-0.40 ± 0.049
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

Change from Baseline to Week 6 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 6

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)-0.85 ± 0.051-0.93 ± 0.051-0.90 ± 0.050-0.53 ± 0.050
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

Change from Baseline to Week 8 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 8

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)-0.96 ± 0.051-1.04 ± 0.051-0.99 ± 0.051-0.59 ± 0.051
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

Change from Baseline to Week 12 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 12

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)-0.98 ± 0.051-1.03 ± 0.051-0.94 ± 0.050-0.61 ± 0.050
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

Change from Baseline to Week 2 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain) = 3 Severity was assessed by the Investigator at Baseline and Week 2

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)-0.79 ± 0.050-0.83 ± 0.050-0.86 ± 0.050-0.54 ± 0.050
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0004
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

Change from Baseline to Week 6 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 6

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)-0.90 ± 0.051-0.95 ± 0.051-0.97 ± 0.051-0.60 ± 0.051
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

Change from Baseline to Week 8 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 8

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)-1.00 ± 0.052-1.04 ± 0.052-1.06 ± 0.052-0.63 ± 0.052
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

Change from Baseline to Week 12 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 12

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)-1.01 ± 0.051-1.06 ± 0.051-1.04 ± 0.051-0.64 ± 0.051
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · Mixed Models Analysis · p = < 0.0001
SecondarySecondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score

Change from Baseline to Week 12 in FSFI Total Score as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score7.909 (6.748 to 9.070)9.431 (8.261 to 10.601)10.283 (9.133 to 11.434)7.458 (6.315 to 8.602)
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.9075
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0492
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0019
SecondarySecondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal

Change from Baseline to Week 12 in FSFI Domain Score (Arousal) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal0.875 (0.657 to 1.093)1.287 (1.066 to 1.507)1.392 (1.176 to 1.608)0.93 (0.715 to 1.145)
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.9719
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0614
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0085
SecondarySecondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire

Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire0.625 (0.471 to 0.779)0.800 (0.646 to 0.955)0.848 (0.695 to 1.000)0.630 (0.479 to 0.782)
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.9999
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.2855
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.1189
SecondarySecondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication

Change from Baseline to Week 12 in FSFI Domain Score (Lubrication) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication1.834 (1.578 to 2.090)2.242 (1.984 to 2.500)2.299 (2.045 to 2.553)1.595 (1.343 to 1.846)
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.4162
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0013
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0003
SecondarySecondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm

Change from Baseline to Week 12 in FSFI Domain Score (Orgasm) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm1.162 (0.903 to 1.421)1.274 (1.013 to 1.535)1.591 (1.334 to 1.847)1.202 (0.948 to 1.457)
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.9929
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.9634
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0898
SecondarySecondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain

Change from Baseline to Week 12 in FSFI Domain Score (Pain) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain2.173 (1.879 to 2.467)2.548 (2.251 to 2.844)2.514 (2.222 to 2.805)1.930 (1.641 to 2.219)
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.5146
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0099
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0150
SecondarySecondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction

Change from Baseline to Week 12 in FSFI Domain Score (Satisfaction) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction
units on a scaleEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel Capsule
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction1.257 (1.046 to 1.469)1.384 (1.170 to 1.597)1.629 (1.420 to 1.839)1.174 (0.965 to 1.383)
Statistical analysis
  • Estradiol 4mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.9039
  • Estradiol 10mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.3751
  • Estradiol 25mcg Vaginal Softgel Capsule vs Placebo Vaginal Softgel Capsule · ANCOVA · p = 0.0073
Other pre-specifiedPK Substudy - Hormone Concentration Assessments (Serum Estradiol, Estrone and Estrone Conjugates; SHBG)

Blood samples will be obtained from a subset of subjects at pre-selected sites to characterize PK parameters (AUC, tmax, Cmin, Cmax, Cavg) and to measure SHBG

Time frame:
Pre-treatment, Day 2, Weeks 2 and 12

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Estradiol 4mcg Vaginal Softgel Capsule—0/191 (0%)46/191 (24.1%)
Estradiol 10mcg Vaginal Softgel Capsule—3/191 (1.6%)41/191 (21.5%)
Estradiol 25mcg Vaginal Softgel Capsule—4/190 (2.1%)45/190 (23.7%)
Placebo—1/192 (0.5%)66/192 (34.4%)
Most frequent serious events
Most frequent serious events
EventEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo
Atrial fibrillationCardiac disorders0/1910/1911/1900/192
AppendicitisGastrointestinal disorders0/1910/1911/1900/192
EndophthalmitisInfections and infestations0/1910/1911/1900/192
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1910/1911/1900/192
Sinus node dysfunctionCardiac disorders0/1911/1910/1900/192
Ankle fractureInjury, poisoning and procedural complications0/1911/1910/1900/192
ArthralgiaMusculoskeletal and connective tissue disorders0/1911/1910/1900/192
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1911/1910/1900/192
Cervical myelopathyNervous system disorders0/1910/1910/1901/192
Most frequent other events
Most frequent other events
EventEstradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo
HeadacheNervous system disorders12/19114/1916/19015/192
Vaginal dischargeReproductive system and breast disorders5/1916/1914/19013/192
NasopharyngitisInfections and infestations5/1916/1917/19010/192
Vulvovaginal pruritusReproductive system and breast disorders4/1913/1917/19010/192
Back painMusculoskeletal and connective tissue disorders9/1911/1914/1908/192
Urinary tract infectionInfections and infestations5/1915/1918/1904/192
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/1910/1916/1901/192
Upper respiratory infectionInfections and infestations5/1916/1913/1905/192

Baseline characteristics

The modified intent to treat (MITT) population was the primary efficacy population, defined as all ITT subjects who received the treatment to which they were randomized, had baseline values for all co-primary variables, and had at least one post-baseline value for any of the four co-primary variables at any visit.

Age, Categorical
Age, Categorical(Participants)Estradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel CapsuleTotal
<=18 years00000
Between 18 and 65 years148162156151617
>=65 years43293441147
Age, Continuous
Age, Continuous(years)Estradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel CapsuleTotal
Mean59.8 ± 5.9058.5 ± 6.2958.9 ± 6.2659.3 ± 6.0759.1 ± 6.14
Sex: Female, Male
Sex: Female, Male(Participants)Estradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel CapsuleTotal
Female191191190192764
Male00000
Region of Enrollment
Region of Enrollment(participants)Estradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel CapsuleTotal
Canada1310151250
United States178181175180714
Height
Height(centimeters)Estradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel CapsuleTotal
Mean162.7 ± 6.86162.9 ± 6.93162.3 ± 6.37162.2 ± 6.30162.5 ± 6.62
Weight
Weight(kilograms)Estradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel CapsuleTotal
Mean70.4 ± 14.2671.1 ± 13.4970.6 ± 13.770.4 ± 13.670.6 ± 13.74
BMI
BMI(kg/m^2)Estradiol 4mcg Vaginal Softgel CapsuleEstradiol 10mcg Vaginal Softgel CapsuleEstradiol 25mcg Vaginal Softgel CapsulePlacebo Vaginal Softgel CapsuleTotal
Mean26.5 ± 4.8726.8 ± 4.6826.7 ± 4.7926.7 ± 4.5926.7 ± 4.73
08

Study locations

105 sites
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Montogomery Women's Health
    Montgomery, Alabama 36117, United States
  • Cactus Clinical Research
    Mesa, Arizona 85209, United States
  • Arizona Wellness Center for Women
    Phoenix, Arizona 85032, United States
  • Radiant Research
    Scottsdale, Arizona 85251, United States
  • Visions Clinical Research - Tucson
    Tucson, Arizona 85712, United States
  • Sutter East Bay Medical Foundation
    Berkeley, California 94705, United States
  • Torrance Clinical Research Institute Inc
    Lomita, California 90717, United States
  • Futura Research
    Norwalk, California 90650, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • San Diego Sexual Medicine
    San Diego, California 92120, United States
  • Women's Health Care Research Corp.
    San Diego, California 92123, United States
  • Lynn Institute of the Rockies
    Colorado Springs, Colorado 80909, United States
  • Downtown Women's Health Care
    Denver, Colorado 80209, United States
  • Horizons Clinical Research Center
    Denver, Colorado 80220, United States
  • Red Rocks OB/Gyn
    Lakewood, Colorado 80228, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
  • James A. Simon, Women's Health & Research Consultants
    Washington, D.C., District of Columbia 20036, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • Avail Clinical Research
    DeLand, Florida 32720, United States
  • Clinical Physiology Associates
    Fort Myers, Florida 33916, United States
  • UF Health Physicians Women's & REI Springhill
    Gainesville, Florida 32606, United States
  • UF College of Medicine-Jacksonville, Dept. of Obstetrics and Gynecology
    Jacksonville, Florida 32207, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • South Florida Wellness & Clinical Research Institute
    Margate, Florida 33063, United States
  • New Age Medical Research Corporation
    Miami, Florida 33186, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Ideal Clinical Research
    North Miami Beach, Florida 33162, United States
  • Healthcare Clinical Data
    North Miami, Florida 33161, United States
  • Radiant Research
    Pinellas Park, Florida 33781, United States
  • All Women's Healthcare of West Broward
    Plantation, Florida 33324, United States
  • Physician Care Clinical Research
    Sarasota, Florida 34239, United States
  • Comprehensive Clinical Trials
    West Palm Beach, Florida 33409, United States
  • Women's Health Associates
    Atlanta, Georgia 30342, United States
  • Masters of Clinical Research, Inc.
    Augusta, Georgia 30909, United States
  • Soapstone Center for Clinical Research
    Decatur, Georgia 30034, United States
  • WR-Mount Vernon Clinical Research
    Sandy Springs, Georgia 30328, United States
  • Fellows Research Alliance, Inc.
    Savannah, Georgia 31046, United States
  • Advanced Clinical Research
    Boise, Idaho 83642, United States
  • Women's Healthcare Associates P.A.
    Idaho Falls, Idaho 83404, United States
  • Radiant Research
    Chicago, Illinois 60654, United States
  • American Health Network of Indiana, LLC
    Avon, Indiana 46123, United States
  • Lafayette Clinical Research Group
    Lafayette, Indiana 47905, United States
  • Cypress Medical Research Center
    Wichita, Kansas 67226, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Bluegrass Clinical Research, Inc.
    Louisville, Kentucky 40291, United States
  • Horizon Research Group of Opelousas
    Eunice, Louisiana 70535, United States
  • Capital Women's Care
    Frederick, Maryland 21702, United States
  • Maryland Center for Sexual Health
    Lutherville, Maryland 21093, United States
  • ClinSite, LLC
    Ann Arbor, Michigan 48106, United States
  • Beyer Research
    Kalamazoo, Michigan 49009, United States
  • Saginaw Valley Medical Research Group, L.L.C.
    Saginaw, Michigan 48604, United States
  • Montana Health
    Billings, Montana 59102, United States
  • Women's Clinic of Lincoln
    Lincoln, Nebraska 68510, United States
  • Office of Edmond E. Pack, MD
    Las Vegas, Nevada 89113, United States
  • Office of R. Garn Mabey, MD
    Las Vegas, Nevada 89128, United States
  • Lawrence OB-GYN Clinical Research, LLC
    Lawrenceville, New Jersey 08648, United States
  • Rutgers-Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • Women's Health Research Center
    Plainsboro, New Jersey 08536, United States
  • Bosque Women's Care
    Albuquerque, New Mexico 87109, United States
  • Southwest Clinical Research
    Albuquerque, New Mexico 87109, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Suffolk OB/GYN
    Port Jefferson, New York 08536, United States
  • Women's Wellness Clinic
    Durham, North Carolina 27713, United States
  • Pinewest OB-GYN, Inc.
    High Point, North Carolina 27262, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Hawthorne Research
    Winston-Salem, North Carolina 27103, United States
  • Lyndhurst Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Lillestol Research
    Fargo, North Dakota 58103, United States
  • Radiant Research
    Akron, Ohio 44311, United States
  • University of Cincinnati Physicians Company
    Cincinnati, Ohio 45267-0457, United States
  • Rapid Medical Research
    Cleveland, Ohio 44122, United States
  • Columbus Center for Women's Health Research
    Columbus, Ohio 43213, United States
  • HWC Women's Research Center
    Englewood, Ohio 45322, United States
  • Landerbrook Health Center
    Mayfield Heights, Ohio 44124, United States
  • Sunstone Medical Research
    Medford, Oregon 97504, United States
  • The Clinical Trial Center
    Jenkintown, Pennsylvania 19046, United States
  • Clinical Research of Philadelphia
    Philadelphia, Pennsylvania 19114, United States
  • Clinical Trials Research Services
    Pittsburgh, Pennsylvania 15206, United States
  • Fellows Research Alliance, Inc.
    Bluffton, South Carolina 29910, United States
  • Vista Clinical Research
    Columbia, South Carolina 29201, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Chattanooga Medical Research
    Chattanooga, Tennessee 37404, United States
  • Advanced Research Associates
    Corpus Christi, Texas 78414, United States
  • Research Across America
    Dallas, Texas 75234, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390-9032, United States
  • Advances in Health
    Houston, Texas 77030, United States
  • Hwca, Pllc
    Houston, Texas 77054, United States
  • TMC Life Research
    Houston, Texas 77054, United States
  • Stone Oak, LLC dba Discovery Clinical Trials
    San Antonio, Texas 78258, United States
  • National Clinical Research-Norfolk
    Norfolk, Virginia 23502, United States
  • Clinical Research Center, EVMS
    Norfolk, Virginia 23507, United States
  • Virginia Women's Center, Inc.
    Richmond, Virginia 23233, United States
  • National Clinical Research-Richmond, Inc
    Richmond, Virginia 23294, United States
  • Tidewater Clinical Research
    Virginia Beach, Virginia 23456, United States
  • Seattle Women's Health, Research, and Gynecology
    Seattle, Washington 98105, United States
  • North Spokane Women's Health
    Spokane, Washington 99207, United States

Showing the first 100 of 105 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mirkin S, Simon JA, Liu JH, Archer DF, Castro PD, Graham S, Bernick B, Komm B. Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert. Menopause. 2021 May 28;28(9):998-1003. doi: 10.1097/GME.0000000000001801. PubMed 34054104 ↗
  • Constantine G, Millheiser LS, Kaunitz AM, Parish SJ, Graham S, Bernick B, Mirkin S. Early onset of action with a 17beta-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia. Menopause. 2019 Nov;26(11):1259-1264. doi: 10.1097/GME.0000000000001394. PubMed 31688572 ↗
  • Constantine GD, Simon JA, Pickar JH, Archer DF, Bernick B, Graham S, Mirkin S. Estradiol vaginal inserts (4 microg and 10 microg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. Curr Med Res Opin. 2018 Dec;34(12):2131-2136. doi: 10.1080/03007995.2018.1527578. Epub 2018 Sep 28. PubMed 30238814 ↗
  • Constantine GD, Bouchard C, Pickar JH, Archer DF, Graham S, Bernick B, Mirkin S. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women. J Womens Health (Larchmt). 2017 Jun;26(6):616-623. doi: 10.1089/jwh.2016.6187. Epub 2017 Mar 29. PubMed 28355090 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2014
First posted
Oct 1, 2014
Start
Sep 2014
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
May 25, 2017
Last update
May 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02253173
Lead sponsor
TherapeuticsMD
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Sep 2014
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
May 25, 2017
Last update
May 25, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion